BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35768844)

  • 1. Mantle cell lymphoma negative for t(11,14) involving the kidneys: a case report.
    Nassereldine H; Mohty R; Awada H; Abou Dalle I; El-Cheikh J; Bazarbachi A
    J Med Case Rep; 2022 Jun; 16(1):254. PubMed ID: 35768844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
    Hermine O; Hoster E; Walewski J; Bosly A; Stilgenbauer S; Thieblemont C; Szymczyk M; Bouabdallah R; Kneba M; Hallek M; Salles G; Feugier P; Ribrag V; Birkmann J; Forstpointner R; Haioun C; Hänel M; Casasnovas RO; Finke J; Peter N; Bouabdallah K; Sebban C; Fischer T; Dührsen U; Metzner B; Maschmeyer G; Kanz L; Schmidt C; Delarue R; Brousse N; Klapper W; Macintyre E; Delfau-Larue MH; Pott C; Hiddemann W; Unterhalt M; Dreyling M;
    Lancet; 2016 Aug; 388(10044):565-75. PubMed ID: 27313086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vocal cord paralysis during the treatment of mantle cell lymphoma with vincristine.
    Yalin SF; Trabulus S; Yalin AS; Yalin GY; Ongoren S; Altiparmak MR
    Int J Clin Pharm; 2013 Jun; 35(3):306-8. PubMed ID: 23338712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Finnish Lymphoma Group.
    Räty R; Honkanen T; Jantunen E; Jyrkkiö S; Karjalainen-Lindsberg ML; Kuittinen O; Lehto M; Mikkola M; Poikonen E; Rauhala A; Rimpiläinen J; Räsänen A; Siitonen S; Suominen M; Vapaatalo M; Elonen E
    Leuk Lymphoma; 2012 Oct; 53(10):1920-8. PubMed ID: 22397313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
    Burke JM; van der Jagt RH; Kahl BS; Wood P; Hawkins TE; MacDonald D; Hertzberg M; Simpson D; Craig M; Kolibaba K; Issa S; Munteanu M; Victor TW; Flinn IW
    Clin Lymphoma Myeloma Leuk; 2016 Apr; 16(4):182-190.e1. PubMed ID: 26875824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extranodal blastoid/pleomorphic variant of mantle cell lymphoma involving the testis and skin.
    Anusim N; Gupta A; Howard G; Jaiyesimi I
    BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33509883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
    Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
    J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy and prognostic analysis of frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone regimens (VR-CAP) for patients with mantle cell lymphoma].
    Cao YW; Zheng Z; Xu PP; Cheng S; Wang L; Qian Y; Zhao WL
    Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):415-419. PubMed ID: 34218585
    [No Abstract]   [Full Text] [Related]  

  • 10. Non-multiple lymphomatous polyposis form of mantle cell lymphoma in the gastrointestinal tract.
    Tamura S; Ohkawauchi K; Yokoyama Y; Higashidani Y; Daibata M; Hiroi M; Yamamori S; Onishi S
    J Gastroenterol; 2004 Oct; 39(10):995-1000. PubMed ID: 15549454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rare case of primary bone lymphoma of the femur.
    Kiamos A; Boldig K; Gagadam V; Gujarathi R
    BMJ Case Rep; 2023 Jul; 16(7):. PubMed ID: 37474139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
    Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
    Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.
    Rampotas A; Wilson MR; Lomas O; Denny N; Leary H; Ferguson G; McKay P; Ebsworth T; Miller J; Shah N; Martinez-Calle N; Bishton M; Everden A; Tucker D; El-Hassad E; Hennessy B; Doherty D; Prideaux S; Faryal R; Hayat A; Keohane C; Marr H; Gibb A; Pocock R; Lambert J; Lacey R; Elmusharaf N; Clifford R; Eyre TA
    Br J Haematol; 2021 Jul; 194(2):365-377. PubMed ID: 33959947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.
    Linschoten M; Kamphuis JAM; van Rhenen A; Bosman LP; Cramer MJ; Doevendans PA; Teske AJ; Asselbergs FW
    Lancet Haematol; 2020 Apr; 7(4):e295-e308. PubMed ID: 32135128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late-onset meningeal lymphomatosis in mantle cell lymphoma controlled with chemotherapy.
    Alonso JJ; Cánovas A; Riñón MM
    Neurologia (Engl Ed); 2018 Apr; 33(3):201-202. PubMed ID: 27126565
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase 3 study of frontline rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in transplantation-unsuitable mantle cell lymphoma (MCL) patients.
    Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):9-11. PubMed ID: 25768994
    [No Abstract]   [Full Text] [Related]  

  • 17. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
    Wang ML; Jain P; Zhao S; Lee HJ; Nastoupil L; Fayad L; Ok CY; Kanagal-Shamanna R; Hill HA; Yao Y; Hagemeister FB; Westin JR; Fowler N; Samaniego F; Steiner R; Nair R; Iyer SP; Navsaria L; Badillo M; ; Feng L; Xuelin H; Nogueras Gonzalez GM; Xu G; Wagner-Bartak N; Thirumurthi S; Santos D; Tang G; Lin P; Wang SA; Jorgensen J; Yin CC; Li S; Patel KP; Vega F; Medeiros LJ; Flowers CR; Wang L
    Lancet Oncol; 2022 Mar; 23(3):406-415. PubMed ID: 35074072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial.
    Roider T; Wang X; Hüttl K; Müller-Tidow C; Klapper W; Rosenwald A; Stewart JP; de Castro DG; Dreger P; Hermine O; Kluin-Nelemans HC; Grabe N; Dreyling M; Pott C; Ott G; Hoster E; Dietrich S
    Int J Cancer; 2021 Jan; 148(1):150-160. PubMed ID: 32638373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin's lymphoma.
    Wilder DD; Ogden JL; Jain VK
    Clin Lymphoma; 2001 Mar; 1(4):285-92. PubMed ID: 11707843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal change disease associated with newly diagnosed mantle cell lymphoma.
    Khow KS; Yong AS; Yong TY; Kuss BJ; Barbara JA; Li JY
    Ren Fail; 2014 May; 36(4):634-7. PubMed ID: 24502759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.